Cancer Center Support Grant (CCSG)

 描述(申请人提供)：癌症基因和途径研究在新重组的癌症基因和途径(CGP)计划中，专注于研究作为癌症发展和免疫监测基础的具有生物学意义的基因改变和分子途径。这项基础科学计划的主要目标是更好地了解肿瘤发生和癌症免疫学的基本机制，从而定义可用作疾病生物标记物和/或创新抗癌疗法的新分子实体。这是通过三个重叠的研究主题来完成的，这些研究主题集中在1)基因组组织、调控和癌症基因表达，2)细胞增殖、存活和转化，以及3)肿瘤免疫监测。在之前的资助期间取得的主要科学成就包括：在了解受损DNA修复和复制机制方面的进展、新的促进肿瘤的基因改变和癌症基因网络的识别和表征、创新的癌症动物模型的开发以及控制B和T淋巴细胞存活和激活的途径的确定。CGP会员包括54名正式会员和6名准会员，横跨3所学院的16个系(10个基础科学，6个临床)。在上一个预算年度，CGP每年为同行评审研究提供的资金总额为1,036万美元(NCI基金为2美元)，为非同行评审研究项目提供的资金为199万美元。CGP成员具有高度的协作性，在过去4年中撰写或共同撰写了353篇与癌症相关的同行评审出版物，其中17%(n=59)是方案内的，22%(n=77)是方案间的，32%(n=113)是机构间的。49篇稿件发表在影响力较大的期刊上(影响因子10)。富有成效的方案内/方案间和多机构小组在成熟B系肿瘤(骨髓瘤和非霍奇金淋巴瘤)和神经内分泌肿瘤研究方面处于领先地位，并对白血病、乳腺癌、前列腺癌、黑色素瘤、胰腺癌和肝癌等其他人类恶性肿瘤做出了重大贡献。

 DESCRIPTION (provided by applicant): Cancer Genes and Pathways Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of biologically significant genetic alterations and molecular pathways that underlie cancer development and immune surveillance. The primary goal of this basic science program is to better understand fundamental mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2) cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific achievements over the prior funding period include advances in understanding mechanisms of damaged DNA repair and replication, identification and characterization of novel tumor-promoting genetic alterations and cancer gene networks, development of innovative animal models of cancer, and determination of pathways controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding for peer-reviewed research in the last budget year was $10.36 million ($2 NCI funding) and $1.99 million for non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored 353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22% (n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor research, and making major contributions to other human malignancies including leukemias, breast cancer, prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.